Download PDF
Klin Padiatr 2008; 220(6): 392-402
DOI: 10.1055/s-0028-1086037
Mitteilungen

© Georg Thieme Verlag KG Stuttgart · New York

Interdisziplinäre S2-Therapieleitlinie der Juvenilen Idiopathischen Arthritis

Interdisciplinary and Evidence-based Treatment Guideline for Juvenile Idiopathic ArthritisN. Guellac 1 , T. Niehues *
  • 1Zentrum für Kinder und Jugendmedizin, HELIOS Klinikum Krefeld
  • *für die Konsensusgruppe (am Ende des Beitrags)
Further Information

Publication History

Publication Date:
23 October 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Therapie der Juvenilen Idiopathischen Arthritis (JIA) hat zu einer Verbesserung der Lebensqualität von Kindern und Jugendlichen geführt, variiert aber von Behandler zu Behandler noch erheblich. Eine Standardisierung der Therapie auf der Basis von Konsensusempfehlungen bietet die Chance, die Qualität der Versorgung von Kindern und Jugendlichen mit JIA weiter zu verbessern.

Ziel der Untersuchung: Evidenzbasierte S2- Leitlinie zum Thema JIA, basierend auf der bestehenden Leitlinie von 2005.

Methodik: Eine systematische Literaturanalyse wurde durchgeführt. Als Stichwörter wurden verwandt: juvenile idiopathic (rheumatoid) arthritis and therapy; als Suchbegrenzungen (Limits) in PUBMED: humans, published in the last 3 years, all child 0–18 years, clinical trial. Ausgeschlossen wurden Studien zur Diagnostik der JIA, Uveitis, Impfung, Transition und Rofecoxib. Die Autoren der GKJR-Leitlinie von 2005 und Vertreter aus folgenden Fachgesellschaften und Vereinigungen wurden zu professionell moderierten Konsensuskonferenzen eingeladen: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Die Konsensuskonferenzen am 9.5. und 1.8.2007 in Düsseldorf fanden unter >95% Teilnahme statt und die Konsensus-Statements wurden abschließend im Delphiverfahren abgestimmt.

Resultate und Zusammenfassung: Zu den Themen medikamentöse, symptomatische und chirurgische JIA-Therapie wurden Statements im Konsens erarbeitet und nach den Kriterien der evidenzbasierten Medizin bewertet.

Abstract

Treatment of Juvenile Idiopathic Arthritis (JIA) has improved quality of life in children and adolescents suffering from JIA. However, it varies considerably from caregiver to caregiver. Therefore a standardisation of care on the basis of consensus treatment recommendations offers the chance to further improve the quality of care for children and adolescents with JIA. We aimed to establish an interdisciplinary, evidence-based treatment guideline for JIA based on the existing guideline from 2005.

Methods: We did a systematic literature analysis in PUBMED with the key words “juvenile idiopathic (rheumatoid) arthritis” and “therapy”. As limits in PUBMED we used: humans, published in the last 3 years, all child 0–18 years, clinical trial. Studies relating to diagnosis of JIA, Uveitis, vaccination, transition and rofexocibe were excluded. Authors of the 2005 guideline and representatives nominated by different societies were invited to attend the consensus conferences which were hosted by a professional moderator. Following societies were invited: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Consensus conferences took place in Düsseldorf on May 9th and August 1st 2007 and were each attended by more than 95% of the nominated representatives Finally, statements were confirmed in a Delphi method.

Results and Conclusion: Consensus statements regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (EBM).

Schlüsselwörter

Juvenile Idiopathische Arthritis - evidenzbasierte Medizin - Therapieleitlinie - Kinder - Jugendliche - rheumatische Erkrankungen - Konsens

Key words

juvenile idiopathic arthritis - evidence-based medicine - treatment guideline - children - adolescence - consensus

Literatur

  • 1 Adebajo A, Hall M. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis.  Br J Rheumatol. 1998;  37 1240-1242
    CrossrefPubMedGoogle Scholar
  • 2 Andreae J. et al . Effect of glucocorticoid therapy on glucocorticoid receptors in children with autoimmune diseases.  Pediatr Res. 2001;  49 130-135
    CrossrefPubMedGoogle Scholar
  • 3 April KT, Ehrmann Feldman ED, Platt RW. et al . Comparison between children with juvenile idiopathic arthritis (JIA) and their parents concerning perceived quality of life.  Quality of Life Research. 2006;  15 655-661
    CrossrefPubMedGoogle Scholar
  • 4 Arabshahi B, Dewitt EM, Cahill AM. et al . Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis.  Arthritis Rheum. 2005;  52 ((11)) 3563-3569
    CrossrefPubMedGoogle Scholar
  • 5 Breit W. et al . A sub-group specific evaluation of the efficacy of intra-articular triamcinolone hexacetonide in juvenile chronic arthritis.  J Rheumatol. 2000;  27 2696-2702
    PubMedGoogle Scholar
  • 6 Brewer EJ, Giannini EH, Kuzmina N. et al . Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the USA – U.S.S.R. double-blind placebo-controlled trial.  N Engl J Med. 1986;  314 1269-1276
    PubMedGoogle Scholar
  • 7 Buttgereit F. et al . Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology.  Ann Rheum Dis. 2002;  61 718-722
    CrossrefPubMedGoogle Scholar
  • 8 Buttgereit F. Mechanisms and clinical relevance of nongenomic glucocorticoid actions.  Z Rheumatol. 2000;  59 ((Suppl. 2)) 119-123
    PubMedGoogle Scholar
  • 9 Cleary AG. et al . Intra-articular corticoid injections in juvenile idiopathic arthritis.  Arch Dis Child. 2003;  88 192-196
    CrossrefPubMedGoogle Scholar
  • 10 Jong Z De, Munneke M, Zwinderman AH. et al . Is a long term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial.  Arthritis Rheum. 2003;  48 ((9)) 2415-2424
    CrossrefPubMedGoogle Scholar
  • 11 Encke A, Kopp I, Selbmann HK. et al . Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), and Hrsg. Deutsches Instrument zur methodischen Bewertung von Leitlinien: DELBI.  Dt Ärztebl. 2005;  102 (26) A1912-A1913 http://www.delbi.de , – Zugriff am 10.2.2008
    PubMedGoogle Scholar
  • 12 Epps H, Ginnelly L, Utley M. et al . Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis.  Health Technol Assess. 2005;  9 ((39)) 1
    PubMedGoogle Scholar
  • 13 Feldman BM, Grundland B, MacCullough L. et al . Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care.  J Rheumatol. 2000;  27 226-233
    PubMedGoogle Scholar
  • 14 Feldmann W. Evidence-based Pediatrics. 1st ed. BC Decker, Hamilton 2000
  • 15 Fink CW. Overview of corticoid therapy in the different rheumatic diseases of childhood.  Clin Exp Rheumatol. 1991;  9 ((Suppl 6)) 9-13
    PubMedGoogle Scholar
  • 16 Foeldvari I, Burgos-Vargas R, Thon A. et al . High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis.  J Rheumatol. 2002;  29 ((5)) 1079-1083
    PubMedGoogle Scholar
  • 17 Gao JS, Wu H, Tian J. Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and methotrexate.  Zhonghua Er Ke Za Zhi. 2003;  41 435-438
    PubMedGoogle Scholar
  • 18 Giannini EH, Brewer EJ, Miller ML. et al . Ibuprofen suspension in the treatment f juvenile rheumatoid arthritis Pediatric Rheumatology Study Group.  J Pediatr. 1990;  117 645-652
    PubMedGoogle Scholar
  • 19 Haapasaari J, Wuolijoki E, Ylijoki H. Treatment of juvenile rheumatoid arthritis with diclofenac sodium.  Scand J Rheumatol. 1983;  12 325-330
    CrossrefPubMedGoogle Scholar
  • 20 Hebestreit H, Müller-Scholden J, Huppertz HI. Aerobic Fitness and Physical Activity in Patients with HLA B27 Positive Juvenile Spondylarthropathy that is Inactive or in Remission.  J Rheumatol. 1998;  25 1626-1633
    PubMedGoogle Scholar
  • 21 Hoffmann JC, Fischer I, Höhne W. et al . Methodische Grundlagen für die Ableitung von Konsensusempfehlungen.  Zeitschrift für Gastroenterologie. 2004;  42 ((9)) 84-87
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Horneff G, Forster J, Seyberth HW. et al . Arbeitgemeinschaft Kinder- und Jugendrheumatologie. Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept (p75 TNF-alpha receptor immunoglobulin fusion protein. Pharmacotherapy Committee.  Z Rheumatol. 2000;  59 ((6)) 365-369
    CrossrefPubMedGoogle Scholar
  • 23 Horneff G, Schmeling H, Biedermann T. et al . The German etanercept registry for treatment of juvenile idiopathic arthritis.  Ann Rheum Dis. 2004;  1 1
    PubMedGoogle Scholar
  • 24 Huppertz HI. et al . Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth.  J Pediatr. 1995;  127 317-321
    PubMedGoogle Scholar
  • 25 Jones G, Bennell K, Cicuttini F M. Effect of physical activity on cartilage development in healthy kids.  Br J Sports Med. 2003;  37 ((5)) 382-383
    CrossrefPubMedGoogle Scholar
  • 26 Kaiser H. Praxis der Cortisontherapie, ed. Kaiser, Urban und Schwarzenberg, München, 4. Auflage. 1996; 
    PubMed
  • 27 Katsicas MM, Russo RA. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.  Clin Exp Rheumatol. 2005;  23 545-548
    PubMedGoogle Scholar
  • 28 Kimura Y. et al . High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis.  J Rheumatol. 2000;  27 2018-2024
    PubMedGoogle Scholar
  • 29 Klepper SE. Effects of an Eight-Week Physical Conditioning Program on Disease Signs and Symptoms in Children with Chronic Arthritis.  Arthritis Care and Research. 1999;  12 52-60
    CrossrefPubMedGoogle Scholar
  • 30 Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study.  J Rheumatol. 1986;  13 118-123
    PubMedGoogle Scholar
  • 31 Kvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study.  Scand J Rheumatol. 1984;  13 342-350
    CrossrefPubMedGoogle Scholar
  • 32 Langer HE. Patient education – a contribution to improvement of long-term management of patiets with rheumatism.  Z Rheumatol. 1995;  54 207-212
    PubMedGoogle Scholar
  • 33 Laxer RM, Silverman ED, St-Cyr C. et al . A six-month open safety assessment of a naproxen suspension formulation in the therapy of juvenile rheumatoid arthritis.  Clin Ther. 1988;  10 381-387
    PubMedGoogle Scholar
  • 34 Leak AM, Richter MR, Clemens LE. et al . A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis.  Clin Exp Rheumatol. 1988;  6 157-160
    PubMedGoogle Scholar
  • 35 Lequerré T. et al . Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.  Ann Rheum Dis. 2008;  67 ((3)) 302-308 , Epub 2007 Oct 18
    PubMedGoogle Scholar
  • 36 Lovell DJ, Reiff A, Jones OY. et al . Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.  Arthritis Rheum. 2006;  1987-1994
    CrossrefPubMedGoogle Scholar
  • 37 Malleson P, Bennett SM, Mac Kinnon M. et al . Physical Fitness and its Relationship to other Indices of Health Status in Children with Chronic Arthritis.  J Rheumatol. 1996;  23 1059-1065
    PubMedGoogle Scholar
  • 38 Manschwetus H. Quality standards and certification of patient education in rheumatology.  Z Rheumatol. 2003;  62 II21-II23
    PubMedGoogle Scholar
  • 39 Michels H. What is low dose corticosteroid therapy in juvenile idiopathic arthritis? A worldwide questionnaire-based survey.  Z Rheumatol. 2000;  59 ((Suppl. 2)) 127-130
    PubMedGoogle Scholar
  • 40 Müller-Godeffroy E, Lehmann H, Küster. et al . Lebensqualität und psychosoziale Anpassung bei Kindern und Jugendlichen mit juveniler idiopathischer Arthritis und reaktiven Arthritiden.  Zeitschrift für Rheumatologie. 2005;  64 177-187
    CrossrefPubMedGoogle Scholar
  • 41 Niehues T, Horneff G, Michels H. et al . Evidence-based use of methotrexate in children with rheumatic disorders. Consensus statement of the Working Group for Children and Adolescents with Rheumatic Diseases in Germany (AGKJR) and the Working Group.  Pediatric Rheumatology Austria Z Rheumatol. 2004;  63 ((2)) 147-158
    PubMedGoogle Scholar
  • 42 Padeh S, Passwell JH. Intraarticular corticosteroid injection in the management of children with chronic arthritis.  Arthritis Rheum. 1998;  41 1210-1214
    CrossrefPubMedGoogle Scholar
  • 43 Pistoia V, Buoncompagni A, Scribanis R. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis Results of a preliminary study.  Clin Exp Rheumatol. 1993;  11 203-208
    PubMedGoogle Scholar
  • 44 Powell M, Seid M, Szer IS. Efficacy of custom foot orthotics in improving pain and functional status in children with juvenile idiopathic arthritis: a randomized trial.  J Rheum. 2005;  32 ((5)) 943-950
    PubMedGoogle Scholar
  • 45 Prieur AM. The place of corticosteroid therapy in juvenile chronic arthritis in 1992.  J Rheumatol. 1993;  37 32-34
    PubMedGoogle Scholar
  • 46 Rasnake LK, Mervis K, Belpedio K. et al . Child and parent perceptions of child health-related quality of life in rheumatic disease: discrepancies and congruencies for ill and well dyads.  Pediatric Rheumatology Online Journal. 2003;  1 187
    PubMedGoogle Scholar
  • 47 Reiff A, Rawlings DJ, Shaham B. et al . Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis.  J Rheumatol. 1997;  24 2436-2443
    PubMedGoogle Scholar
  • 48 Riddle R, Ryser CN, Morton AA. et al . The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis.  J Pediatr Psychol. 2006;  31 ((3)) 262-271 , Epub 2005 May 4
    PubMedGoogle Scholar
  • 49 Ruperto N. et al . A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.  Arthritis Rheum. 2007;  56 ((9)) 3096-3106
    CrossrefPubMedGoogle Scholar
  • 50 Ruperto N, Kuzmina N, Pachanov E. et al . A randomized trial oftwo dose regimen of meloxicam compared to naproxen oral suspension in juvenile idiopathic arthritis.  Arthritis Rheum. 2003;  48 ((9 (Suppl.)) S90-S91
    CrossrefPubMedGoogle Scholar
  • 51 Ruperto N, Murray KJ, Gerloni V. et al . A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.  Arthritis Rheum. 2004;  50 2191-2201
    CrossrefPubMedGoogle Scholar
  • 52 Sanden S. et al . Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases.  J Rheumatol. 2000;  27 1265-1270
    PubMedGoogle Scholar
  • 53 Schaller JG. Corticosteroids in juvenile rheumatoid arthritis.  Arthritis Rheum. 1977;  20 ((Suppl 2)) 537-543
    PubMedGoogle Scholar
  • 54 Selbmann HK, Kopp I. Implementierung von Leitlinien in den Versorgungsalltag.  Die Psychiatrie. 2005;  1 ((2)) 33-38
    PubMedGoogle Scholar
  • 55 Silverman E, Mouy R, Spiegel L. et al . Leflunomide or methotrexate for juvenile rheumatoid arthritis.  N Engl J Med. 2005;  352 1655-1666
    CrossrefPubMedGoogle Scholar
  • 56 Simon D. et al . Linear growth in children suffering from juvenile idiopatic arthritis requiring steroid therapy: natural history and effect of growth hormone treatment on linear growth.  J Pediatr Endocrinol Metab. 2001;  14 ((Suppl 6)) 1483-1486
    PubMedGoogle Scholar
  • 57 Singh-Grewal D, Wright V, Bar-Or O. et al . Pilot study of fitness training and exercise testing in polyarticular childhood arthritis.  Arthritis Rheum. 2006;  55 364-372
    CrossrefPubMedGoogle Scholar
  • 58 Singh-Grewal D. The effects of vigorous exercise training on physical function in children with arthritis: a randomized, controlled, single-blinded trial.  Arthritis Rheum. 2007;  57 ((7)) 1202-1210
    CrossrefPubMedGoogle Scholar
  • 59 Stoeber E, Sänger L. Erfahrungen mit Indometazin in der Langzeittherapie der juvenilen rheumatoiden Arthritis.  Arzneimittelforschung. 1971;  21 ((11)) 1865-1866
    PubMedGoogle Scholar
  • 60 Stritter FT, Tresolini CP, Reeb KG. The Delphi Technique in Curriculum Development.  Teaching and Learning in Medicine. 1994;  6 ((2)) 136-141
    PubMedGoogle Scholar
  • 61 Takken T, Der Net J Van, Kuis W. et al . Aquatic fitness training for children with juvenile idiopathic arthritis.  Rheumatology (Oxford). 2003;  1408-1414
    CrossrefPubMedGoogle Scholar
  • 62 Takken T, Net J Van der, Kuis W. et al . Physical activity and health related physical fitness in children withjuvenileidiopathicarthritis.  Ann Rheum Dis. 2003;  62 ((9)) 885-889
    CrossrefPubMedGoogle Scholar
  • 63 Toledo MM, Martini G, Gigante C. et al . Is there a role for arthroscopic synovectomy in oligoarticular juvenile idiopathic arthritis?.  J Rheumatol. 2006;  33 1868-1872
    PubMedGoogle Scholar
  • 64 Rossum MA van, Fiselier TJ, Franssen MJ. et al . Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study Dutch Juvenile Chronic Arthritis Study Group.  Arthritis Rheum. 1998;  41 808-816
    CrossrefPubMedGoogle Scholar
  • 65 Rossum MA van, Fiselier TJ, Franssen MJ. et al . Long-term outcome of Juvenile Idiopathic Arthritis following a placebo controlled trial: sustained benefits of early sulfasalazin treatment. Dutch Juvenile Chronic Arthritis Study Group.  Arthritis Rheum Dis. 2007;  66 1518-1524
    PubMedGoogle Scholar
  • 66 Schnakenburg K von. et al .Leitlinien Kinder- und Jugendmedizin. Rheumatologie Abschnitt H1: 1–15, Elsevier, 11. Lieferung 2005
  • 67 Wagner N. Juvenile idiopathische Arthritis – Medikamentöse Therapie. In Bassler/Forster/Antes Evidenz basierte Pädiatrie, 1, Auflage. Thieme Verlag 2001
  • 68 Yokota S. et al . Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.  Lancet. 2008;  371 ((9617)) 998-1006
    CrossrefPubMedGoogle Scholar
  • 69 Zulian F. et al . Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis.  Rheumatology. 2003;  42 1254-1259
    CrossrefPubMedGoogle Scholar
  • 70 Zulian F, Martini G, Gobber D. et al . Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial.  Rheumatology (Oxford). 2004;  43 ((10)) 1288-1291 , Epub 2004 Jul 13
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse

Prof. Dr. Tim Niehues

Zentrum für Kinder- und Jugendmedizin

HELIOS Klinikum Krefeld

Lutherplatz 40

47805 Krefeld

Phone: +49/2151/32 23 01

Fax: +49/2151/32 23 34

Email: tim.niehues@helios-kliniken.de

      >